Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**



Namaste Enters Into Non-Binding LOI With CannMart, a Late Stage ACMPR Applicant

  • Namaste will purchase all of the issued and outstanding shares in the capital of CannMart, a late stage applicant under the Access to Cannabis for Medical Purposes Regulations
  • CannMart submitted its application to become a “sales only” licensed producer of medical cannabis


Hub On AGORACOM/ Read Release 

Message: More important points on Fourier... NNT

6. Evolocumab reduced both the primary and secondary composite end points. But the absolute risk reduction was modest, at 1.5%. The authors estimate that 74 patients would need to take evolocumab to prevent a cardiovascular death, MI, or stroke.

7. The benefits of evolocumab came in the prevention of nonfatal events: stroke was lower by 0.4%,, myocardial infarction lower by 1.2%, and coronary revascularization by 1.5%.

8. Evolocumab did not reduce cardiovascular or death from any cause. There was not even a trend for improvement. This is important. See point number 10.

9. The shortness of follow-up of FOURIER deserves mention. On the upside, the Kaplan Meier curves for both the primary and secondary end points looked to be separating over time. This makes sense biologically, as the benefits of exposure to LDL would accrue over time. But so would potential side effects, such as diabetes and neurocognitive effects. The mean age of patients in FOURIER was 63 years; LDL lowering is not a 2-year proposition. The heart and blood vessels are not the only important parts of the body.

New Message
Please login to post a reply